Drug Giant Roche Is Planning To Buy Biotech Firm With Some Potential Game-Changers In Its Pipeline

August 27, 2014 10:50 PM

2 0

Drug Giant Roche Is Planning To Buy Biotech Firm With Some Potential Game-Changers In Its Pipeline

Roche Holding AG’s planned $US8 billion purchase of InterMune Inc is centered around hopes for blockbuster sales of its lung drug, but the smaller company’s development pipeline may end up giving the Swiss drugmaker a far bigger bang for its buck.

Industry analysts have forecast annual sales of about $US2 billion for the pulmonary fibrosis treatment, pirfenidone, once it gains U.S. approval, giving Roche a valuable addition to its respiratory franchise.

Also read: New Zealand PM John Key announces resignation

Read more

To category page

Loading...